SCHEMBL16061453

SCHEMBL16061453

Cc1cc(Nc2nc(C(F)(F)F)ccc2N)on1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EDNRA P25101 1/20 0.43
▸ HSP90AA1 P07900 1/20 0.40
▸ HSP90AB1 P08238 1/20 0.40
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ ATF1 P18846 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ SYK P43405 3/20 0.34
▸ IGF1R P08069 1/20 0.34
▸ PTK2 Q05397 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ GLA P06280 1/20 0.33
▸ TKT P29401 2/20 0.33
▸ IRAK4 Q9NWZ3 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ KMT2A Q03164 2/20 0.32
▸ MAPT P10636 1/20 0.32
▸ JAK2 O60674 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17481366 0.83 EDNRA (0.42) EDNRAHDAC1HDAC8HDAC6SYK
SCHEMBL16062179 0.80 FGFR4 (0.41) EDNRAHDAC1HDAC8HDAC6ATF1
SCHEMBL18193377 0.74 ALDH1A1 (0.38) EDNRAHDAC1HDAC8HDAC6ATF1
SCHEMBL30543749 0.74 ALDH1A1 (0.38) EDNRAHDAC1HDAC8HDAC6ATF1
SCHEMBL10280708 0.71 MAT2A (0.40) HSP90AA1HSP90AB1SYKALDH1A1PTGS2
SCHEMBL13730254 0.69 MAPT (0.44) SYKALDH1A1PTGS2KMT2AMAPT
SCHEMBL17586644 0.68 EDNRA (0.42) EDNRAHDAC1ALDH1A1SMN1; SMN2GLA
SCHEMBL5743149 0.67 LMNA (0.44) HSP90AA1HSP90AB1KMT2AKDM4EMEN1
SCHEMBL18196421 0.65 TRPA1 (0.43) HSP90AA1HSP90AB1SYKMAPT
SCHEMBL180808 0.65 HSP90AA1 (0.44) HSP90AA1HSP90AB1ALDH1A1TKTPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970277-B1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2021-07-28 — — EP disclosed
EP-2970277-B1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2021-07-28 — — EP disclosed
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2019-01-03 — — US disclosed
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2019-01-03 — — US disclosed
US-10106536-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2018-10-23 — — US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 — — US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 — — US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 — — US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 — — US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 — — US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 — — US disclosed
EP-2970277-A2 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS Knopp Biosciences LLC (US) 2016-01-20 — — EP disclosed
WO-2014145852-A2 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2014-09-18 — — WO disclosed
WO-2014145852-A2 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106536-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KCNA7, KCNA2, KCNK17 EDNRA 2786/4885HSP90AA1 3969/4885HSP90AB1 3958/4885
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 EDNRA 2786/4885HSP90AA1 3969/4885HSP90AB1 3958/4885
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 EDNRA 2816/4885HSP90AA1 3933/4885HSP90AB1 3976/4885
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 EDNRA 2786/4885HSP90AA1 3969/4885HSP90AB1 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback